Polaryx Therapeutics, Inc. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number remained flat by 0.0% to $4.19M in Q1 2026 compared to the prior quarter.
An increase suggests higher levels of equity-based retention incentives, while a decrease may indicate a maturing compensation cycle.
This is the count of non-vested equity instruments, such as restricted stock units or performance shares, that have been...
Standard metric for companies using equity-based compensation; peers vary based on their specific compensation mix and vesting schedules.
other_share_based_compensation_arrangement_by_share_base_57b8b4| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $2.67M | $4.19M | $4.19M |
| QoQ Change | — | +56.7% | +0.0% |
| YoY Change | — | +56.7% | — |